(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization International Bureau





(43) International Publication Date 18 December 2003 (18.12.2003)

PCT

(10) International Publication Number WO 03/104488 A1

(51) International Patent Classification⁷: G01N 33/53, 33/68

C12Q 1/68,

(21) International Application Number: PCT/CA03/00865

(22) International Filing Date: 6 June 2003 (06.06.2003)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data: 60/387,231

7 June 2002 (07.06.2002) US

(71) Applicant (for all designated States except US): CANCER CARE ONTARIO [CA/CA]; Provincial Research Office, Room 238 Botterell Hall, Queen's University, Kingston, Ontario K7L 3N6 (CA).

(72) Inventor; and

(75) Inventor/Applicant (for US only): LEE, Jonathan, M. [CA/CA]; 31 Claremont Drive, Hamilton, Ontario L9C 3N3 (CA).

(74) Agents: SCRIBNER, Stephen, J. et al.; Parteq Innovations, Room 1625, Biosciences Complex, Queen's University at Kingston, Kingston, Ontario K7L 3N6 (CA).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: EEF1A2 FOR USE IN THE PROGNOSIS, DIAGNOSIS AND TREATMENT OF CANCER

(57) Abstract: Methods and kits for diagnosing and prognosticating cancer via detection of *EEF1A2* and/or *EEF1A2* are provided. Also provided are methods for treating cancer via inhibition of expression and/or activity of *EEF1A2* and screening assays to identify new anticancer agents based upon their ability to inhibit *EEF1A2* expression and/or activity. The methods and kits of the present invention are particularly useful in the prognosis, diagnosis and treatment of ovarian, breast and colorectal cancer.

A. CLASSIFICATION OF SUBJECT MATTER IPC 7 C12Q1/68 G01N33/53

G01N33/68

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

 $\begin{tabular}{ll} Minimum documentation searched (classification system followed by classification symbols) \\ IPC 7 C12Q C12N \\ \end{tabular}$

Documentation searched other than minimum documentation to the extent that such documents are included. In the fields searched

Electronic data base consulted during the International search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, BIOSIS, EMBASE, MEDLINE

C. DOCUM	ENTS CONSIDERED TO BE RELEVANT			
Category °	Citation of document, with indication, where appropriate, of the	he relevant passages	Relevant to claim No.	
Y	WO 98 09655 A (FISHER PAUL B; UNIV COLUMBIA (US)) 12 March 1998 (1998-03-12) page 1-3; figures 1-5 page 17 -page 22; claims 1-26; example 2		1-29	
Υ	WO 00 71708 A (BOURDILLON MARI INST NAT SANTE RECH MED (FR); 30 November 2000 (2000-11-30) page 1 -page 2 page 14	1-29		
	·	-/		
X Fur	ther documents are listed in the continuation of box C.	Patent family members are listed	in annex.	
considered to be of particular relevance "E" earlier document but published on or after the international filling date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filling date but		cited to understand the principle or the invention "X" document of particular relevance; the cannot be considered novel or cannot involve an inventive step when the de "Y" document of particular relevance; the cannot be considered to involve an indocument is combined with one or ments, such combination being obvicin the art.	 "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled 	
Date of the	actual completion of the international search 22 October 2003	Date of mailing of the International se	arch report	
	mailing address of the ISA	Authorized officer		

2 0


C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT				
Category °	Citation of document, with Indication, where appropriate, of the relevant passages	Relevant to claim No.		
Υ	GOPALKRISHNAN RAHUL V ET AL: "Translational infidelity and human cancer: Role of the PTI-1 oncogene" INTERNATIONAL JOURNAL OF BIOCHEMISTRY AND CELL BIOLOGY, vol. 31, no. 1, January 1999 (1999-01), pages 151-162, XP002257186 ISSN: 1357-2725 the whole document	1-29		
Y	KUANG WAYNE W ET AL: "Differential screening and suppression subtractive hybridization identified genes differentially expressed in an estrogen receptor-positive breast carcinoma cell line" NUCLEIC ACIDS RESEARCH, vol. 26, no. 4, 15 February 1998 (1998-02-15), pages 1116-1123, XP002257188 ISSN: 0305-1048 abstract; table 2	1-29		
Υ	EDMONDS B T ET AL: "Elongation factor-1 alpha is an overexpressed actin binding protein in metastatic rat mammary adenocarcinoma." JOURNAL OF CELL SCIENCE. ENGLAND NOV 1996, vol. 109 (Pt 11), November 1996 (1996-11), pages 2705-2714, XP002257189 ISSN: 0021-9533 abstract page 2707 -page 2708; table 2	1-29		
Y	CORMIER PATRICK: "Translation factors: From protein synthesis to cell cycle regulation and tumorigenesis" M-S (MEDECINE SCIENCES), vol. 16, no. 3, March 2000 (2000-03), pages 378-385, XP009018839 ISSN: 0767-0974 abstract page 382, column 3, paragraph 3 -page 383, column 2	1-29		
	- ·			



PCT 03/00865

	ation) DOCUMENTS CONSIDERED TO BE RELEVANT	
Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	LUND A ET AL: "Assignment of human elongation factor 1-alpha genes: EEFTA maps to chromosome 6q14 and EEF1A2 to 20q13.3" GENOMICS, vol. 36, no. 2, 1996, pages 359-361, XP002257191 ISSN: 0888-7543 cited in the application the whole document	1-29
Α	BISCHOFF C ET AL: "The Human Elongation Factor 1 A-2 Gene (EEF1A2): Complete Sequence and Characterization of Gene Structure and Promoter Activity" GENOMICS, ACADEMIC PRESS, SAN DIEGO, US, vol. 68, no. 1, 15 August 2000 (2000-08-15), pages 63-70, XP004437861 ISSN: 0888-7543 the whole document	1-29
P,X	ANAND NISHA ET AL: "Gene encoding protein elongation factor EEF1A2 is a putative oncogene in ovarian cancer" NATURE GENETICS, vol. 31, no. 3, July 2002 (2002-07), pages 301-305, XP002257192 ISSN: 1061-4036 the whole document	1-29





Box I	Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)
This Inte	mational Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:
1. X	Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:
	Although claims 4 to 6 and claims 24 to 28 embrace methods of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2.	Claims Nos.: because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
з. 🗌	Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).
Box II	Observations where unity of invention is lacking (Continuation of item 2 of first sheet)
This Inte	emational Searching Authority found multiple inventions in this international application, as follows:
1.	As all required additional search fees were timely paid by the applicant, this international Search Report covers all searchable claims.
2.	As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
з. 🗀	As only come of the required additional agersh feet was timely acid by the applicant this leterational Court Depart
». Ц	As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4.	No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:
Remark	on Protest The additional search fees were accompanied by the applicant's protest.
	No protest accompanied the payment of additional search fees.

INTERM ONAL SEARCH REPORT Info on patent family members

Intern Application No
PCT - 03/00865

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9809655	A 12-03-1998	AU 4644297 A EP 0925074 A1 WO 9809655 A1 US 2002090355 A1	26-03-1998 30-06-1999 12-03-1998 11-07-2002
WO 0071708	A 30-11-2000	FR 2793798 A1 WO 0071708 A2	24-11-2000 30-11-2000